Advertisement
At close: 04:00PM EST
After hours:
| Previous Close | 5.17 |
| Open | 5.20 |
| Bid | 5.08 x 200 |
| Ask | 5.18 x 200 |
| Day's Range | 5.08 - 5.32 |
| 52 Week Range | 2.27 - 8.40 |
| Volume | |
| Avg. Volume | 1,327,301 |
| Market Cap | 547.893M |
| Beta (5Y Monthly) | 1.23 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.03 |
| Earnings Date | Nov 14, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.00 |
Pharma VoiceThe Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.
GlobeNewswireAnnexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to seven new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on November 12, 2024, in accord
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.